Exploratory analyses, clinical context and practical quality-improvement questions from Dr John Gillespie.
OpenPrescribing × CVDPREVENT
An exploratory OpenPrescribing and CVDPREVENT analysis of the high-dose CCB to ACE inhibitor/ARB ratio, and why the decision that matters happens before anyone reaches the top dose.
Dr John Gillespie · 10 min · 26 August 2026
NHS England QOF 2025/26
NHS England moved 141 QOF points into cardiovascular prevention for 2025/26 and retired 32 indicators to pay for it. The 2025/26 data show the same lever working in both directions.
Dr John Gillespie · 12 min · 27 August 2026
CVDPREVENT March 2026
CVDPREVENT's first national snapshot of SGLT2 treatment in chronic kidney disease and heart failure finds a twofold gap between ICBs. London leads on the kidney and heart-failure measures, but not on diabetes.
Dr John Gillespie · 11 min · 30 August 2026